Vasoactive intestinal peptide increases hepatic transduction and reduces innate immune response following administration of helper-dependent Ad.
Helper-dependent adenoviral vectors (HDAd) are effective tools for liver-directed gene therapy because they can mediate long-term transgene expression in the absence of chronic toxicity. However, high vector doses required for efficient hepatocyte transduction by intravascular delivery result in systemic vector dissemination and dose-dependent activation of the innate immunity. Therefore, strategies to achieve high-efficiency hepatocyte transduction using low vector doses and/or to reduce the acute elevations of proinflammatory cytokines and chemokines may have significant clinical potential. Vasoactive intestinal peptide (VIP) is an endogenous neuropeptide involved in the regulation of hepatic blood flow and plays an important role as modulator of immune functions. Here, we show that VIP pretreatment in mice is able to increase hepatocyte transduction by HDAd, decrease vector uptake by the spleen, reduce elevation of proinflammatory serum cytokines interleukin (IL)-6 and IL-12, and reduce serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) following intravenous HDAd injection. VIP pretreatment also resulted in a reduction in the expression of the chemokines macrophage-inflammatory protein 2 (MIP-2), monocyte chemotactic protein 1 (MCP-1), and regulated on activation normal T-cell expressed and secreted (RANTES) in the livers of mice injected with HDAd. These results suggest that VIP can improve the therapeutic index of HDAd by increasing hepatocyte transduction efficiency while reducing cytokine and chemokine expression following intravascular delivery of HDAd.
Vetrini
Francesco
F
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030, USA.
Brunetti-Pierri
Nicola
N
Palmer
Donna J
DJ
Bertin
Terry
T
Grove
Nathan C
NC
Finegold
Milton J
MJ
Ng
Philip
P
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D016207:Cytokines / Q000378:metabolism; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000235:genetics; D018664:Interleukin-12 / Q000378:metabolism; D008099:Liver / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D016133:Polymerase Chain Reaction; D013154:Spleen / Q000187:drug effects / Q000378:metabolism; D014161:Transduction, Genetic; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
D016207:Cytokines; D018664:Interleukin-12; D014660:Vasoactive Intestinal Peptide
Curr Gene Ther. 2009 Oct;9(5):329-40
19860648
Gastroenterology. 1981 Aug;81(2):356-75
6113188
Cephalalgia. 2006 Aug;26(8):992-1003
16886936
Gastroenterology. 2003 Apr;124(4):961-71
12671893
Cold Spring Harb Protoc. 2011 Jul 01;2011(7):867-70
21724820
Mol Ther. 2009 Feb;17(2):327-33
19050700
J Immunol. 2008 Apr 1;180(7):4931-8
18354218
Hum Gene Ther. 1999 Oct 10;10(15):2515-26
10543616
J Immunol. 2000 Sep 15;165(6):3051-7
10975815
Mol Ther. 2005 Jul;12(1):99-106
15963925
Mol Ther. 2001 May;3(5 Pt 1):697-707
11356075
J Immunol. 2006 Nov 1;177(9):5920-7
17056516
Hum Gene Ther. 1999 Apr 10;10(6):965-76
10223730
Ann N Y Acad Sci. 2006 Jul;1070:190-5
16888164
J Leukoc Biol. 2005 Aug;78(2):491-502
15857940
Hum Gene Ther. 2002 Jan 1;13(1):143-54
11779418
Arthritis Res Ther. 2005;7(5):R1034-45
16207319
J Virol. 2004 Jun;78(11):5966-72
15140994
Eur J Immunol. 2000 Nov;30(11):3236-46
11093139
Hum Gene Ther. 2006 Mar;17(3):264-79
16544976
Mol Ther. 2003 Nov;8(5):846-52
14599819
Gene Ther. 2007 Apr;14(7):604-12
17235290
Immunol Invest. 2005;34(2):153-69
15921157
Clin Hemorheol Microcirc. 2000;23(2-4):85-94
11321464
Mol Ther. 2007 Apr;15(4):732-40
17285138
Arch Physiol Biochem. 2001 Oct;109(4):377-82
11935377
Hum Gene Ther. 2006 Apr;17(4):391-404
16610927
Hum Gene Ther. 2004 Jan;15(1):35-46
14965376
Res Exp Med (Berl). 1986;186(2):151-65
2872707
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):1053-8
11792830
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13282-7
11687662
Peptides. 2008 Jun;29(6):948-56
18359536
J Virol. 2000 May;74(9):3941-7
10756005
Viral Immunol. 1992 Fall;5(3):195-200
1418317
Digestion. 2002;66(3):186-92
12481165
J Neuroimmunol. 2000 Oct 2;110(1-2):97-105
11024538
Gene Ther. 2004 Oct;11(20):1523-31
15269718
Mol Ther. 2001 May;3(5 Pt 1):708-22
11356076
J Biol Chem. 2001 Jan 5;276(1):369-80
11029467
Biochem Biophys Res Commun. 2003 Mar 7;302(2):275-83
12604342
Mol Ther. 2008 May;16(5):931-41
18388926
Comp Hepatol. 2002 Aug 23;1(1):1
12437787
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):3930-5
15753292
Mol Ther. 2004 Oct;10(4):792-8
15451463
J Immunol. 2007 Feb 1;178(3):1767-73
17237426
Hum Gene Ther. 2005 Jul;16(7):811-20
16000063
J Virol. 2004 May;78(10):5368-81
15113916